Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Cancer Therapeutics
  • View item
  • Home
  • ICR Divisions
  • Cancer Therapeutics
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Accelerating drug development for neuroblastoma - New Drug Development Strategy: an Innovative Therapies for Children with Cancer, European Network for Cancer Research in Children and Adolescents and International Society of Paediatric Oncology Europe Neuroblastoma project.

Thumbnail
View/Open
Supporting information (63.31Kb)
Date
2017-08
ICR Author
Chesler, Louis
Marsden,
Author
Moreno, L
Caron, H
Geoerger, B
Eggert, A
Schleiermacher, G
Brock, P
Valteau-Couanet, D
Chesler, L
Schulte, JH
De Preter, K
Molenaar, J
Schramm, A
Eilers, M
Van Maerken, T
Johnsen, JI
Garrett, M
George, SL
Tweddle, DA
Kogner, P
Berthold, F
Koster, J
Barone, G
Tucker, ER
Marshall, L
Herold, R
Sterba, J
Norga, K
Vassal, G
Pearson, AD
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Introduction Neuroblastoma, the commonest paediatric extra-cranial tumour, remains a leading cause of death from cancer in children. There is an urgent need to develop new drugs to improve cure rates and reduce long-term toxicity and to incorporate molecularly targeted therapies into treatment. Many potential drugs are becoming available, but have to be prioritised for clinical trials due to the relatively small numbers of patients. Areas covered: The current drug development model has been slow, associated with significant attrition, and few new drugs have been developed for neuroblastoma. The Neuroblastoma New Drug Development Strategy (NDDS) has: 1) established a group with expertise in drug development; 2) prioritised targets and drugs according to tumour biology (target expression, dependency, pre-clinical data; potential combinations; biomarkers), identifying as priority targets ALK, MEK, CDK4/6, MDM2, MYCN (druggable by BET bromodomain, aurora kinase, mTORC1/2) BIRC5 and checkpoint kinase 1; 3) promoted clinical trials with target-prioritised drugs. Drugs showing activity can be rapidly transitioned via parallel randomised trials into front-line studies. Expert opinion: The Neuroblastoma NDDS is based on the premise that optimal drug development is reliant on knowledge of tumour biology and prioritisation. This approach will accelerate neuroblastoma drug development and other poor prognosis childhood malignancies.
URI
https://repository.icr.ac.uk/handle/internal/1194
DOI
https://doi.org/10.1080/17460441.2017.1340269
Collections
  • Cancer Therapeutics
  • Clinical Studies
  • Molecular Pathology
Subject
Humans
Neuroblastoma
Antineoplastic Agents
Prognosis
Drug Evaluation, Preclinical
Drug Design
Time Factors
Adolescent
Child
Randomized Controlled Trials as Topic
Molecular Targeted Therapy
Research team
Paediatric Solid Tumour Biology and Therapeutics
Language
eng
License start date
2017-08
Citation
Expert opinion on drug discovery, 2017, 12 (8), pp. 801 - 811

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.